



**Interagency Coordinating Committee on
the Validation of Alternative Methods**

Developing a Strategic Roadmap To Establish New Approaches for Evaluating the Safety of Chemicals and Medical Products in the United States

Warren Casey, PhD, DABT

Director, NICEATM

NTP Interagency Center for the Evaluation of Alternative
Toxicological Methods

Agency for Toxic Substances and Disease Registry • Consumer Product Safety Commission • Department of Agriculture
Department of Defense • Department of Energy • Department of the Interior • Department of Transportation
Environmental Protection Agency • Food and Drug Administration • National Institute for Occupational Safety and Health
National Institutes of Health • National Cancer Institute • National Institute of Environmental Health Sciences
National Library of Medicine • Occupational Safety and Health Administration


FAQ

- International harmonization is critically important, why is this a “US” effort?




FAQ

- How is this different?



2007



2016

FAQ

- How is this different?
 - Driven by Federal agencies (“top down” vs “bottom up”)
 - Includes both chemicals and medical products
 - Paired with implementation plans that will be tracked and publically reported




Why do we need new approaches?

Drivers for Change

- **Ethics**



- **Efficiency**



- **Public Health (Human Relevance)**



- **Legislation**





Subcommittee Hearing

Hearing on FY2017 National Institutes of Health Budget Request

Labor, Health and Human Services, Education, and Related Agencies

Date: Thursday, April 7, 2016

Time: 10:00 AM

Location: Dirksen Senate Office Building 138




In Francis Collins' recent testimony to the congressional subcommittee with NIH budget oversight responsibility, he offered that :

“Animal safety testing for environmental chemicals and drugs will largely be replaced by tissue chips and iPS cells in 10 years.”

“.....giving results that are more accurate, at lower cost and higher throughput.”

It is difficult for evolving institutional practices to keep pace with revolutionary advances in science and technology



Wyss Institute researchers and a multidisciplinary team of collaborators seek to build and link 10 human organs-on-chips to mimic whole body physiology. The system will incorporate the Institute's Human Lung-on-a-Chip (top) and Human Gut-on-a-Chip (bottom).



1928



2017








“VAMs”







“Myth of Many Methods”


The 4th R;
RETHINK

Regulatory
Acceptance

Industry Adoption




- **Animal Data as the Reference for Validation**



- **Insufficient Human Data**



- **Institutional Resistance**



- **Harmonization**





15 Years Out: Reinventing ICCVAM

February 1, 2013 Editorials Comments Off

Linda S. Birnbaum

Director, NIEHS and NTP, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North



Linda S. Birnbaum

The interagency agenda now be *driven by agencies* that will ultimately implement and utilize the recommended methods

Fit for purpose / Context of Use

Background

- **2015 SACATM** – Identified Roadmap as a priority activity
- **2016 SACATM** – Meeting focused on Roadmap
- **Feb 2017** – 2-day face-to-face Interagency meeting to start process of establishing mission / vision / goals / objectives

65 participants + 20 WebEx / Professional Facilitation

Agency for Toxic Substances and Disease
Registry

Consumer Product Safety Commission

Department of Agriculture

Department of Energy

Department of the Interior

Department of Transportation

Environmental Protection Agency

Food and Drug Administration

Occupational Safety and Health Administration

National Institute for Occupational
Safety and Health

National Cancer Institute

National Institute of Environmental
Health Sciences

National Library of Medicine

National Institutes of Health

National Institute of Standards and
Technology

Department of Defense

Department of Energy

A strategic roadmap is a plan that defines where we are, where we want to go, and how to get there



- Helps federal agencies identify consensus goals and coordinate key activities
- Provides a framework to support the planning and coordination of technology development
- Facilitates communication and collaboration within and between government agencies, stakeholders, and international partners

NEW APPROACHES

collaboration

partnerships

share resources

agency capacity

promote health

competitiveness

decision-making

sustainable

relevance

efficiency

transform understanding

overcome bottlenecks

risk management

validated tools

specificity

working cooperatively

diverse partners

innovation

science

early identification

better predict

global adoption

solutions

technology

improvements

new information

rigorous

encourage adoption

quality

modernize toxicology

regulatory science

technology transfer

National leadership


share expertise

cost effective

scientific tools

computational tools

best science



Disclaimer: *"The draft outline was developed by representatives from ICCVAM agencies along with other Federal partners and interagency workgroups. The text represents a generalized perspective that does not reflect opinions or policy of any specific agency and may not be applicable to all Federal agencies."*


VISION: To establish new approaches for evaluating the safety of chemicals and medical products in the United States that will increase confidence in alternative methods and improve their relevance to human health outcomes while maximizing efficiency and maintaining a commitment to replace, reduce, and refine animal use.

MISSION: Federal agencies, the regulated community, non-governmental organizations and other technical experts will work together to explore new approaches for evaluating the safety of chemicals and medical products that will **(1)** help guide the development of new tools to support regulatory and research needs **(2)** use knowledge of human and animal biology as appropriate to help establish confidence in new approaches, and **(3)** facilitate and encourage the implementation and use of these new approaches by Federal agencies and regulated industries.



Start Here!





Example Draft Goals



Regularly assess the plan and communicate both the progress and challenges in its implementation

Example Draft Goals



**Identify and communicate
the decision contexts and
needs of Federal agencies**

Example Draft Goals



Create resources that will foster development and utilization of new or enhanced approaches

Example Draft Goals



Create resources that will foster development and utilization of new or enhanced approaches


Hosted Session: Tools for Validation and Regulatory Application of Alternative Methods (Wednesday, March 15, 1:30-2:30 CC Room 337)


An Integrated Chemical Environment to Support 21st Century Toxicology Bell et al. Abstract 2935 P429 3/15/17 (Wed), 1:15-4:30.


24 May
Public Forum
NIH, Bethesda

18-19 Sep
SACATM
NIH, Bethesda

15 Dec
Publish Final







Highlights for SOT 2017



56th
Annual Meeting
and ToxExpo™

Baltimore,
Maryland

March 12–16, 2017

- **Replacing Animals for Acute Systemic Toxicity Testing: A U.S. Strategy and Roadmap**
 - Poster Session on Regulation and Policy, Tuesday, March 14, 1:15-4:30 p.m.
- **ICCVAM Tools for Validation and Regulatory Application of Alternative Methods**
 - Exhibitor-hosted session, Wednesday, March 15, 1:30-2:30 p.m., CC Room 337
- **Prediction of Skin Sensitization Potency Using Machine Learning Approaches**
Abstract 2195, P409, 3/15/17 (Wed), 1:15-4:30

Thank you!

Questions?

